Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))

Jacqueline S. Garcia; Ronan T. Swords; Gail J. Roboz; Meagan A. Jacoby; Guillermo Garcia-Manero; Wan Jen Hong; Xiaoqing Yang; Ying Zhou; Uwe Platzbecker; David P. Steensma; Johannes E. Wolff; Pierre Fenaux

doi:10.1016/j.leukres.2021.106581

Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))

Jacqueline S. Garcia, Ronan T. Swords, Gail J. Roboz, Meagan A. Jacoby, Guillermo Garcia-Manero, Wan Jen Hong, Xiaoqing Yang, Ying Zhou, Uwe Platzbecker, David P. Steensma, Johannes E. Wolff, Pierre Fenaux

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Since the publication of this article the authors have identified an error in Figure 1b. The original plot used the incorrect variable data for the Y-axis and this has now been corrected to match the corresponding X-axis (as shown below). This correction neither changes the interpretation of the data nor does it alter the overall conclusions of the study. Corrected Figure 1b.

Original language	English (US)
Article number	106581
Journal	Leukemia Research
Volume	105
DOIs	https://doi.org/10.1016/j.leukres.2021.106581
State	Published - Jun 2021
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2021.106581

Fingerprint

Dive into the research topics of 'Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))'. Together they form a unique fingerprint.

Cite this

Garcia, J. S., Swords, R. T., Roboz, G. J., Jacoby, M. A., Garcia-Manero, G., Hong, W. J., Yang, X., Zhou, Y., Platzbecker, U., Steensma, D. P., Wolff, J. E., & Fenaux, P. (2021). Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555)). Leukemia Research, 105, Article 106581. https://doi.org/10.1016/j.leukres.2021.106581

Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555)). / Garcia, Jacqueline S.; Swords, Ronan T.; Roboz, Gail J. et al.
In: Leukemia Research, Vol. 105, 106581, 06.2021.

Research output: Contribution to journal › Comment/debate › peer-review

Garcia, JS, Swords, RT, Roboz, GJ, Jacoby, MA, Garcia-Manero, G, Hong, WJ, Yang, X, Zhou, Y, Platzbecker, U, Steensma, DP, Wolff, JE & Fenaux, P 2021, 'Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))', Leukemia Research, vol. 105, 106581. https://doi.org/10.1016/j.leukres.2021.106581

Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ et al. Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555)). Leukemia Research. 2021 Jun;105:106581. doi: 10.1016/j.leukres.2021.106581

Garcia, Jacqueline S. ; Swords, Ronan T. ; Roboz, Gail J. et al. / Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555)). In: Leukemia Research. 2021 ; Vol. 105.

@article{a8a3e65c8c4848de9b8db500d894c120,

title = "Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))",

abstract = "Since the publication of this article the authors have identified an error in Figure 1b. The original plot used the incorrect variable data for the Y-axis and this has now been corrected to match the corresponding X-axis (as shown below). This correction neither changes the interpretation of the data nor does it alter the overall conclusions of the study. Corrected Figure 1b.",

author = "Garcia, {Jacqueline S.} and Swords, {Ronan T.} and Roboz, {Gail J.} and Jacoby, {Meagan A.} and Guillermo Garcia-Manero and Hong, {Wan Jen} and Xiaoqing Yang and Ying Zhou and Uwe Platzbecker and Steensma, {David P.} and Wolff, {Johannes E.} and Pierre Fenaux",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = jun,

doi = "10.1016/j.leukres.2021.106581",

language = "English (US)",

volume = "105",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))

AU - Garcia, Jacqueline S.

AU - Swords, Ronan T.

AU - Roboz, Gail J.

AU - Jacoby, Meagan A.

AU - Garcia-Manero, Guillermo

AU - Hong, Wan Jen

AU - Yang, Xiaoqing

AU - Zhou, Ying

AU - Platzbecker, Uwe

AU - Steensma, David P.

AU - Wolff, Johannes E.

AU - Fenaux, Pierre

PY - 2021/6

Y1 - 2021/6

N2 - Since the publication of this article the authors have identified an error in Figure 1b. The original plot used the incorrect variable data for the Y-axis and this has now been corrected to match the corresponding X-axis (as shown below). This correction neither changes the interpretation of the data nor does it alter the overall conclusions of the study. Corrected Figure 1b.

AB - Since the publication of this article the authors have identified an error in Figure 1b. The original plot used the incorrect variable data for the Y-axis and this has now been corrected to match the corresponding X-axis (as shown below). This correction neither changes the interpretation of the data nor does it alter the overall conclusions of the study. Corrected Figure 1b.

UR - http://www.scopus.com/inward/record.url?scp=85107088681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107088681&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2021.106581

DO - 10.1016/j.leukres.2021.106581

M3 - Comment/debate

C2 - 33896620

AN - SCOPUS:85107088681

SN - 0145-2126

VL - 105

JO - Leukemia Research

JF - Leukemia Research

M1 - 106581

ER -

Corrigendum to “A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival” (Leukemia Research (2021) 104, (S0145212621000564), (10.1016/j.leukres.2021.106555))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this